Trial
NCT02765997
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Unmanipulated UCB
Why stopped
IRB Disapproval
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-05